The clinical record on MK-677, known generically as ibutamoren, is best read as a development program that worked pharmacologically and stalled clinically. A cluster of phase I and phase II trials from the 1990s and early 2000s established that a single daily oral dose reliably raises growth hormone and IGF-1, yet the two flagship therapeutic trials, in hip fracture recovery and in Alzheimer disease, both missed their primary endpoints. That gap between a reproducible endocrine effect and an absent functional benefit is the throughline of the entire literature, and it is why the compound remains investigational rather than an approved drug.
The published clinical record establishes MK-677 as a potent, orally active growth hormone secretagogue with a reproducible endocrine effect that never produced the functional clinical benefit needed for regulatory approval of any indication.
The endocrine response is the single most reproducible result in the entire MK-677 literature, and it is what carried the program forward despite the later efficacy failures. Across phase I and phase II studies, a 25 mg once-daily oral dose raised mean 24-hour growth hormone by roughly 50 to 90 percent and lifted serum IGF-1 by about 40 to 90 percent from baseline, into a range comparable to physiologic young-adult levels. Because the compound mimics ghrelin at the GH secretagogue receptor, it amplifies the body's own GH pulses rather than imposing a flat exogenous level, preserving the natural pulsatile rhythm and feedback architecture that injected growth hormone bypasses.
A 25 mg daily oral dose of MK-677 raised mean 24-hour growth hormone by approximately 50 to 90 percent and serum IGF-1 by roughly 40 to 90 percent from baseline, an elevation sustained across a two-year trial with little evidence of tachyphylaxis.
Controlled trials did record a real anabolic signal on body composition, but the literature defines the finding by the gap between that signal and any functional outcome. In healthy older men and women, twelve months of daily dosing raised fat-free mass by roughly one to one and a half kilograms over placebo, measured chiefly by DXA and confirmed across more than one cohort. The reported problem is that the added lean tissue did not translate into measurable gains in muscle strength, gait speed, or stair-climbing power, and a portion of the early weight change reflected fluid retention rather than new contractile tissue.
Twelve months of MK-677 dosing increased fat-free mass by roughly one to one and a half kilograms over placebo on DXA, but the trials recorded no matching gain in muscle strength, gait speed, or stair-climbing power, which investigators read as a negative result.
Research on the skeleton produced a suggestive but ultimately unconfirmed signal. Treatment raised biochemical markers of bone turnover, including formation markers such as osteocalcin and procollagen peptides alongside markers of resorption, indicating that the IGF-1 elevation was driving active remodeling. An increase in remodeling is a necessary precursor to a density change, not the same thing, and because new bone is laid down slowly, a genuine increase in bone mineral density on DXA typically takes longer than the twelve to twenty-four month windows most trials allowed.
MK-677 measurably activated bone turnover, raising both formation and resorption markers, but no trial ran long enough to confirm a clinically meaningful gain in bone mineral density, leaving the skeletal benefit unproven.
A small body of polysomnography work found that MK-677 shifted sleep architecture in a direction usually considered favorable. In a controlled crossover study, treatment increased the proportion of slow wave sleep, the deep restorative stage, and lengthened REM sleep as well, with the effect described as more pronounced in younger adults than older ones in the populations tested. The mechanistic link is biologically coherent, since the ghrelin and GH-releasing systems are tied to slow wave sleep regulation, but the studies were not powered to show that participants felt more rested or functioned better the next day, so the clinical value remains exploratory.
A controlled crossover polysomnography study found MK-677 increased the proportion of slow wave sleep and lengthened REM sleep, a real measurable pharmacodynamic effect on sleep staging whose subjective or next-day clinical value was never formally established.
The hip fracture program was one of the two flagship therapeutic trials, and it ended in failure on its primary endpoint. The rationale was direct: older patients recovering from a hip fracture are catabolic, weak, and at high risk of losing independence, so an oral agent that boosts the GH-IGF-1 axis and adds lean mass might accelerate functional recovery. The trial enrolled frail elderly patients after surgical repair and treated them across a recovery window, but the results did not show a clinically meaningful improvement in the functional recovery endpoints that mattered for independence.
The hip fracture recovery trial treated frail older patients after surgical repair and failed its primary functional-recovery endpoint, reinforcing that added lean mass on a scan did not become usable strength in the population the anabolic rationale was meant to help.
The Alzheimer disease trial was a substantial, multi-year, placebo-controlled study in patients with mild to moderate disease, and it returned a clearly negative result. Across a treatment period running roughly a year, MK-677 did not slow the rate of cognitive decline or functional impairment compared with placebo on standard dementia rating instruments. The rationale rested on IGF-1's neurotrophic properties and its decline with age, so restoring a more youthful IGF-1 level was hypothesized to protect aging neurons. IGF-1 rose as designed in the treated group, which makes the cognitive null result all the more instructive about the limits of the endocrine effect.
A multi-year placebo-controlled trial in mild to moderate Alzheimer disease found MK-677 produced the expected IGF-1 rise yet did not slow cognitive decline versus placebo, removing dementia from the list of plausible indications.
The tolerability profile across the studies is reasonably consistent and is dominated by effects that follow predictably from activating the GH-IGF-1 axis. The most commonly reported events were increased appetite, an on-target consequence of the ghrelin-mimetic mechanism, along with mild fluid retention presenting as peripheral edema, transient muscle or joint pain and stiffness, and occasional fatigue. These mirror the effects of growth hormone therapy, and the compound was tolerated well enough at the standard dose for trials to run one to two years without widespread early discontinuation, though in frailer older populations the fluid and glucose effects lower the acceptable risk threshold.
The reported adverse events, increased appetite, mild peripheral edema, transient muscle and joint pain, and fatigue, follow predictably from GH-IGF-1 axis activation and were tolerable for one to two years at the standard dose, but they carry more weight in frail older patients.
The metabolic findings are the most clinically consequential safety signal in the MK-677 record. Across studies, treatment produced a modest but real reduction in insulin sensitivity, accompanied by small increases in fasting blood glucose and, over the longer one to two year trials, slight rises in HbA1c. The mechanism is intrinsic to the drug class, since growth hormone is a counter-regulatory hormone that antagonizes insulin action in peripheral tissues, so any agent that durably raises GH and IGF-1 nudges the body toward insulin resistance. In healthy younger participants the shift was generally mild, but the direction of effect is the concern in anyone with impaired fasting glucose or type 2 diabetes.
MK-677 produced a modest but real reduction in insulin sensitivity with small rises in fasting glucose and HbA1c over one to two years, an intrinsic GH-axis effect that is mild in healthy younger participants but clinically meaningful in those with pre-existing glucose intolerance.
The evidence base is reproducible in its core findings but narrow in scope and largely dated. Most foundational work came from the 1990s and early 2000s and concentrated on healthy older adults, the group in whom the age-related decline of the GH-IGF-1 axis made restoration most appealing, supported by studies in healthy younger volunteers used to characterize the pharmacology. Beyond the healthy-aging cohorts, the program reached into post-surgical hip fracture patients, mild to moderate Alzheimer disease patients, and smaller studies in catabolic or GH-deficient states, with the two-year healthy-elderly trial as the principal source of durability data.
| Dimension | What the record covers |
|---|---|
| Era | Mostly 1990s and early 2000s |
| Core population | Healthy older adults, plus healthy younger volunteers |
| Clinical cohorts | Hip fracture, Alzheimer disease, catabolic or GH-deficient states |
| Longest exposure | A single two-year healthy-elderly trial |
| Trial size | Dozens to a few hundred participants per study |
The MK-677 evidence base rests mostly on 1990s and early 2000s studies in healthy older adults of dozens to a few hundred participants each, with the two-year healthy-elderly trial the longest continuous human exposure and few trials running beyond twelve months.
Several structural limitations temper how far the clinical record can be pushed. The trials were generally small by pivotal-drug standards, leaving them underpowered to detect uncommon adverse events or resolve modest subgroup differences, and most ran for a year or less, with the two-year study an outlier. That short horizon leaves the central long-term safety question only partially answered, because IGF-1 is a mitogenic, pro-proliferative signal, and a theoretical concern about sustained elevation and its relationship to tissue growth and cancer risk over many years was never settled by a trial run long or large enough to address it.
The published clinical record on MK-677 is built on small, mostly year-or-shorter trials using decades-old methods, leaving the long-term safety question of sustained IGF-1 elevation and theoretical cancer risk unresolved by any trial run long or large enough to settle it.
No drug regulator has ever approved MK-677 for any therapeutic indication, and that fact organizes the entire clinical record. The compound advanced through phase I and phase II development, but the pivotal therapeutic trials, most visibly the hip fracture and Alzheimer programs, failed to meet their primary efficacy endpoints, and a clear, clinically meaningful benefit on a defined endpoint is the central requirement for approval. Without it, the reproducible endocrine effect alone was never sufficient, so the program stalled and the compound remains investigational, prohibited in sports under anti-doping rules and, where sold, sold outside the approved-drug framework.
No drug regulator has ever approved MK-677 for any indication; it advanced only through phase I and II, the pivotal hip fracture and Alzheimer trials failed their primary endpoints, and it remains an unapproved investigational compound, banned in sport and sold outside the approved-drug framework.
Educational use only. This article describes what the published scientific and clinical literature reports about MK-677. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
